Delin Qi1, Yi Zhang2, Hongli Li1, Ruotian Wang2, Kun Qian2. 1. Department of Cardiac Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. 2. Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Abstract
BACKGROUND: Lung cancer is one of the most dangerous diseases to human health, with high morbidity and mortality. It can be cured by surgery at early stage, therefore, the early detection and early treatment of lung cancer are especially important. Serum tumor markers play an important role in the detection and diagnosis of lung cancer. Galectin-3 is known to be expressed in a variety of malignant tumors. This study was to explore the serum levels of Galectin-3 and its clinical significance in non-small cell lung cancer (NSCLC) patients. METHODS: The serum levels of Galectin-3 in peripheral blood were detected by enzyme linked immunosorbent assay (ELISA) in 69 NSCLC patients and 77 cases of healthy control subjects, and compared between the two groups. Then we analyze the correlations between the serum levels of Galectin-3 and the clinical features of lung cancer. RESULTS: The serum levels of Galectin-3 in NSCLC patients were significantly higher than those of healthy control subjects (P<0.01). The serum levels of Galectin-3 with lymph node metastasis were significantly higher than those of patients without lymph node metastasis (P<0.01), and N2 lymph node metastasis had higher levels of serum Galectin-3 than those of N1 lymph node metastasis (P<0.01). Clinical stage III and stage IV patients had higher levels of serum Galectin-3 than those of clinical stage I and clinical stage II (P<0.05). CONCLUSIONS: Our study showed the serum levels of Galectin-3 are highly expressed in NSCLC patients and are significantly related to lymph node metastasis. It may be a potential tumor marker for lung cancer.
BACKGROUND:Lung cancer is one of the most dangerous diseases to human health, with high morbidity and mortality. It can be cured by surgery at early stage, therefore, the early detection and early treatment of lung cancer are especially important. Serum tumor markers play an important role in the detection and diagnosis of lung cancer. Galectin-3 is known to be expressed in a variety of malignant tumors. This study was to explore the serum levels of Galectin-3 and its clinical significance in non-small cell lung cancer (NSCLC) patients. METHODS: The serum levels of Galectin-3 in peripheral blood were detected by enzyme linked immunosorbent assay (ELISA) in 69 NSCLCpatients and 77 cases of healthy control subjects, and compared between the two groups. Then we analyze the correlations between the serum levels of Galectin-3 and the clinical features of lung cancer. RESULTS: The serum levels of Galectin-3 in NSCLCpatients were significantly higher than those of healthy control subjects (P<0.01). The serum levels of Galectin-3 with lymph node metastasis were significantly higher than those of patients without lymph node metastasis (P<0.01), and N2 lymph node metastasis had higher levels of serum Galectin-3 than those of N1 lymph node metastasis (P<0.01). Clinical stage III and stage IV patients had higher levels of serum Galectin-3 than those of clinical stage I and clinical stage II (P<0.05). CONCLUSIONS: Our study showed the serum levels of Galectin-3 are highly expressed in NSCLCpatients and are significantly related to lymph node metastasis. It may be a potential tumor marker for lung cancer.
Entities:
Keywords:
Cancer metastasis; Galectin-3; Lung neoplasms
对两组数据采用SPSS 17.0统计软件(SPSS INC, IL, USA)进行统计学分析。由于所测肺癌患者血清Galectin-3浓度均为计量资料, 所有数据进行正态性检验, 不符合正态分布的数据进行非参数检验(Mann-Whitney U test), 符合正态分布并具有方差齐性的数据进行t检验; 全部显著性检验均为双侧检验, 当P < 0.05时被认为差异有统计学意义, P < 0.01表示差异具有显著统计学意义。
结果
外周血血清Galectin-3浓度比较
NSCLC患者外周血血清Galectin-3浓度显著高于健康人群[(1.38±0.75) ng/mL vs (0.92±0.53) ng/mL], 两者之间差异有显著统计学意义(P=0.002)。早期肺癌患者(Ⅰ期+Ⅱ期)外周血血清Galectin-3浓度与健康人群比较[(1.09±0.82) ng/mL vs (0.92±0.53) ng/mL], 差异无统计学意义(P > 0.05)。NSCLC患者外周血血清Galectin-3浓度与患者年龄、性别、吸烟史、肿瘤大小、组织学分型及分化程度无相关性。见表 1。
1
肺癌患者血清Galectin-3浓度与临床特征的关系(Mean±SD, ng/mL)
Correlation between serum levels of Galectin-3 and clinical features (Mean±SD, ng/mL)
Characteristic
n
Galectin-3 level
P
Age (yr)
0.062
≤60
20
1.40±0.64
> 60
49
1.19±0.85
Gender
0.965
Male
48
1.26±0.82
Female
21
1.31±0.90
Smoking history
0.672
Yes
40
1.28±0.79
No
29
1.16±0.63
Tumor size
0.825
≤3 cm
22
1.32±0.97
> 3 cm
47
1.21±0.74
Histology
0.652
Squamous carcinoma
26
1.18±0.80
Adenocarcinoma
43
1.29±0.85
Pathological grade
0.185
Well and moderately differentiated
16
1.38±0.80
Poorly differentiated
21
1.06±0.64
Lymph node metastasis
0.005
Yes
25
1.63±0.87
No
44
1.03±0.72
Lymph node metastasis
0.007
N1
12
0.88±0.38
N2
8
1.76±0.89
Clinical stage
0.044
Ⅰ+Ⅱ
40
1.09±0.82
Ⅲ+Ⅳ
29
1.50±0.82
肺癌患者血清Galectin-3浓度与临床特征的关系(Mean±SD, ng/mL)Correlation between serum levels of Galectin-3 and clinical features (Mean±SD, ng/mL)
不同临床特征间Galectin-3浓度的比较
① 有淋巴结转移的NSCLC患者血清Galectin-3浓度显著高于无淋巴结转移患者血清Galectin-3浓度。②同侧纵隔内及(或)隆突下淋巴结(N2)转移患者与同侧支气管周围及(或)同侧肺门淋巴结以及肺内淋巴结(N1)转移患者比较, 血清Galectin-3浓度显著升高。③晚期肺癌患者(Ⅲ期+Ⅳ期)血清Galectin-3浓度显著高于早期肺癌患者(Ⅰ期+Ⅱ期)血清Galectin-3浓度。见表 1。
Authors: Samira Bernardino Ramos do Prado; Gustavo R C Santos; Paulo A S Mourão; João Paulo Fabi Journal: Int J Biol Macromol Date: 2018-12-22 Impact factor: 6.953
Authors: Tariq Sethi; Alison C MacKinnon; Lynda Vuong; Eleni Kouverianou; Claire M Rooney; Brian J McHugh; Sarah E M Howie; Christopher D Gregory; Stuart J Forbes; Neil C Henderson; Fredrik R Zetterberg; Ulf J Nilsson; Hakon Leffler; Paul Ford; Anders Pedersen; Lise Gravelle; Susan Tantawi; Hans Schambye Journal: Cancer Res Date: 2019-01-23 Impact factor: 12.701